查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600112

免疫療法藥物市場：按類型、應用和最終用戶分類 - 全球預測 2025-2030

Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines-Based Therapy), Application (Autoimmune Disease, Infectious Disease, Neurology), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年免疫療法藥物市場價值為1756.4億美元，預計2024年將達到1969.6億美元，複合年成長率為12.35%，預計到2030年將達到3970.2億美元。

免疫療法藥物 免疫療法是製藥業中一個強大且不斷發展的部分，旨在增強或改變免疫系統對抗癌症、感染疾病和其他疾病的能力。免疫療法的需求在於其能夠更精確地靶向特定細胞，可能比化療等傳統治療方法產生更少的副作用。這些治療劑具有廣泛的用途，包括腫瘤學、感染疾病管理、自體免疫疾病和過敏治療。最終用途主要是醫院、癌症研究機構和專科診所。重要的成長要素包括生物技術的進步、癌症和慢性病盛行率的上升以及研發資金的增加。個人化醫療和聯合治療存在關鍵機會，可以提高治療效果並減少治療抵抗。也建議採用數位健康技術並與生物技術公司合作進行藥物共同開發，以開發潛在的市場機會。然而，高昂的開發成本、嚴格的監管核准以及免疫反應的複雜性等挑戰使市場擴張變得複雜。智慧財產權問題和對其長期影響的有限理解進一步阻礙了進展。創新可以集中於開發生物標記以更好地對患者進行分層，改善遞送機制以提高藥物穩定性和療效，以及擴大現有藥物的適應症。繼續研究了解腫瘤微環境和免疫景觀仍然至關重要。該市場的特點是技術進步迅速、製藥巨頭之間競爭激烈、戰略聯盟和併購數量不斷增加。總體而言，該領域的相關人員需要對新的科學發現保持警惕，對技術整合保持靈活性，並投資創新的臨床試驗，以充分發揮免疫療法的潛力。

主要市場統計
基準年[2023] 1756.4億美元
預測年份 [2024] 1969.6億美元
預測年份 [2030] 3970.2億美元
複合年成長率（%） 12.35%

市場動態：揭示快速發展的免疫治療市場的關鍵市場洞察

供需的動態交互作用正在改變免疫治療藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球慢性病盛行率上升
    • 新免疫治療藥物的核准和上市增加
    • 消費者對個人化醫療的需求不斷成長
  • 市場限制因素
    • 核准流程複雜且漫長
  • 市場機會
    • 政府更重視開發先進的免疫療法藥物
    • 私人公司和新興生物企業的投資增加
  • 市場挑戰
    • 關於藥物副作用的安全性擔憂日益增加

波特五力：駕馭免疫治療藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解免疫治療市場的外部影響

外部宏觀環境因素在塑造免疫治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解免疫治療藥物市場的競爭格局

免疫療法藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣免疫療法藥物市場供應商的績效評估

FPNV定位矩陣是評估免疫療法藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃免疫治療藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，免疫治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界慢性病的增加
      • 新免疫治療藥物的核准和上市增加
      • 消費者對個人化醫療的需求增加
    • 抑制因素
      • 核准流程複雜且漫長
    • 機會
      • 各國政府越來越注重開發先進技術
      • 私營部門和新興生物技術Start-Ups的投資增加
    • 任務
      • 對藥物副作用的安全性疑慮日益增加
  • 市場區隔分析
    • 類型：癌症疫苗需求隨著癌症發生率的增加而增加
    • 應用：自體免疫疾病治療的新應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章免疫治療藥物市場：依類型

  • 癌症疫苗
  • 查核點抑制劑
  • 細胞激素治療
  • 單株抗體
  • T細胞療法

第7章免疫治療藥物市場：依應用分類

  • 自體免疫疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學

第8章免疫治療藥物市場：依最終用戶分類

  • 醫院
  • 專科診所

第9章美洲免疫治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太免疫治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲免疫療法藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Hanmi Pharmaceutical 與默克合作開創晚期癌症治療的協同免疫療法
    • Pathios Therapeutics 已獲得 2500 萬美元的 B 輪融資，以推進免疫治療臨床試驗並推動長期腫瘤學創新。
    • 輝瑞收購 Seagen 是為了利用先進的 ADC 技術加速創新癌症治療，加強其在腫瘤學領域的領導地位並擴大其全球影響力。
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Affimed Therapeutics
  • AstraZeneca PLC
  • Atara Biotherapeutics
  • Biogen Inc.
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Celldex Therapeutics
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • ElevateBio
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samyang Holdings Corporation
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Turnstone Biologics
Product Code: MRR-521BAA36EBB6

The Immunotherapy Drugs Market was valued at USD 175.64 billion in 2023, expected to reach USD 196.96 billion in 2024, and is projected to grow at a CAGR of 12.35%, to USD 397.02 billion by 2030.

Immunotherapy drugs, a potent and evolving segment in the pharmaceutical industry, are designed to enhance or modify the immune system's ability to fight cancer, infectious diseases, and other disorders. The necessity of immunotherapy lies in its ability to target specific cells more precisely, offering potentially fewer side effects compared to traditional therapies like chemotherapy. Applications of these drugs span oncology, infectious disease management, autoimmune disorders, and allergy treatment. End-use is primarily within hospitals, cancer research institutions, and specialty clinics. Critical growth factors include advancements in biotechnology, rising prevalence of cancer and chronic diseases, and increased funding for research and development. Key opportunities exist in personalized medicine and combination therapies, which can enhance the efficacy and reduce resistance to treatment. Embracing digital health technologies and conducting collaborations for co-developing drugs with biotech firms are also recommended strategies for harnessing potential market opportunities. However, challenges such as high development costs, stringent regulatory approvals, and the complexity of immune responses complicate market expansion. Intellectual property issues and limited understanding of long-term effects further hinder progress. Innovation can be focused on the development of biomarkers for better patient stratification, improving delivery mechanisms to enhance drug stability and effectiveness, and expanding indications for existing drugs. Continuous research into understanding tumor microenvironments and immune landscapes remain pivotal. The market is characterized by rapid technological advancements, high competition among pharmaceutical giants, and an increasing number of strategic partnerships and mergers. Overall, stakeholders in the field should stay vigilant to emerging scientific discoveries, adapt flexibly to technological integrations, and invest in innovative clinical trials to optimize immunotherapy's full potential.

KEY MARKET STATISTICS
Base Year [2023] USD 175.64 billion
Estimated Year [2024] USD 196.96 billion
Forecast Year [2030] USD 397.02 billion
CAGR (%) 12.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunotherapy Drugs Market

The Immunotherapy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • The rising incidence of chronic diseases globally
    • Increasing approval and launch of new immunotherapy drugs
    • Growing demand for personalized medicine among consumers
  • Market Restraints
    • Complex and lengthy approval processes
  • Market Opportunities
    • Growing government emphasis on development of advanced immunotherapy drugs
    • Rising investments from private sectors and emerging biotech startups
  • Market Challenges
    • Emerging safety concerns of side effects of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Immunotherapy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunotherapy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunotherapy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunotherapy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunotherapy Drugs Market

A detailed market share analysis in the Immunotherapy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunotherapy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunotherapy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunotherapy Drugs Market

A strategic analysis of the Immunotherapy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunotherapy Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Affimed Therapeutics, AstraZeneca PLC, Atara Biotherapeutics, Biogen Inc., Boston Scientific Corporation, Bristol-Myers Squibb Company, CARsgen Therapeutics, Celldex Therapeutics, Cipla Ltd., Dr. Reddy's Laboratories Ltd., ElevateBio, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Samyang Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Turnstone Biologics.

Market Segmentation & Coverage

This research report categorizes the Immunotherapy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cancer Vaccines, Checkpoint Inhibitors, Cytokines-Based Therapy, Monoclonal Antibodies, and T-cell Therapy.
  • Based on Application, market is studied across Autoimmune Disease, Infectious Disease, Neurology, and Oncology.
  • Based on End-User, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. The rising incidence of chronic diseases globally
      • 5.1.1.2. Increasing approval and launch of new immunotherapy drugs
      • 5.1.1.3. Growing demand for personalized medicine among consumers
    • 5.1.2. Restraints
      • 5.1.2.1. Complex and lengthy approval processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing government emphasis on development of advanced immunotherapy drugs
      • 5.1.3.2. Rising investments from private sectors and emerging biotech startups
    • 5.1.4. Challenges
      • 5.1.4.1. Emerging safety concerns of side effects of drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing demand for cancer vaccines with the rising prevalence of cancer
    • 5.2.2. Application: Emerging application for autoimmune disease therapy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immunotherapy Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Cancer Vaccines
  • 6.3. Checkpoint Inhibitors
  • 6.4. Cytokines-Based Therapy
  • 6.5. Monoclonal Antibodies
  • 6.6. T-cell Therapy

7. Immunotherapy Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Autoimmune Disease
  • 7.3. Infectious Disease
  • 7.4. Neurology
  • 7.5. Oncology

8. Immunotherapy Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics

9. Americas Immunotherapy Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Immunotherapy Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Immunotherapy Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Hanmi Pharmaceutical and Merck forge partnership to pioneer synergistic immunotherapy for advanced cancer treatment
    • 12.3.2. Pathios Therapeutics secures USD 25 Million in series B to propel immunotherapy treatments into clinical trials and drive long-term oncology innovations
    • 12.3.3. Pfizer acquires Seagen to accelerate innovative cancer therapies with advanced ADC technology, strengthening leadership in oncology and expanding global impact
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Affimed Therapeutics
  • 3. AstraZeneca PLC
  • 4. Atara Biotherapeutics
  • 5. Biogen Inc.
  • 6. Boston Scientific Corporation
  • 7. Bristol-Myers Squibb Company
  • 8. CARsgen Therapeutics
  • 9. Celldex Therapeutics
  • 10. Cipla Ltd.
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. ElevateBio
  • 13. F. Hoffmann-La Roche AG
  • 14. Gilead Sciences, Inc.
  • 15. GlaxoSmithKline PLC
  • 16. Johnson & Johnson Services, Inc.
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Samyang Holdings Corporation
  • 22. Sanofi S.A.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Turnstone Biologics

LIST OF FIGURES

  • FIGURE 1. IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNOTHERAPY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNOTHERAPY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023